首页> 外文OA文献 >A phaseIIIrandomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – theTEAM‐ET2·0 trial

【2h】

A phaseIIIrandomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – theTEAM‐ET2·0 trial

机译：相对于必要血小板血症患者的两种不同的Anagrelide配方的疗效和安全性，可以比较两种不同的Anagrelide配方的疗效和安全性 - Theteam-et2·0试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Heinz Gisslinger; Veronika Buxhofer‐Ausch; Juri Hodisch; Atanas Radinoff; Elena Karyagina; Slawomira Kyrcz‐Krzemień; Kudrat Abdulkadyrov; Rolandas Gerbutavicius; Anait Melikyan; Sonja Burgstaller; Marek Hus; Janusz Kłoczko; Vera Yablokova; Nikolay Tzvetkov; Malgorzata Całbecka; Tatyana Shneyder; Krzysztof Warzocha; Mindaugas Jurgutis; Kamil Kaplanov; Bernd Jilma; Christian Schoergenhofer; Christoph Klade;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2 center dot 0 trial [J] . Gisslinger Heinz, Buxhofer-Ausch Veronika, Hodisch Juri, British Journal of Haematology . 2019,第4期

机译：III期随机，多期，双盲，有效控制试验，以比较两种不同的血小板血症患者的两种不同的Anagrelide配方的疗效和安全性 - Team-et 2中心Dot 0试验
2. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial [J] . Hong Soon Jun, Jeong Han Saem, Ahn Jeong Cheon, Clinical therapeutics . 2018,第2期

机译：III期，多中心，随机，双盲，活性比较试验，以比较与ezetimibe和罗萨凡汀单一的高胆固醇血症患者的疗效和安全性的疗效和安全性：I-ROSETTE（ILDONGROSUVASTATIMIBE用于高胆固醇血症）随机控制审判
3. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial [J] . Chen Yu Hong, Huang Chien‐Ning, Cho Young Min, Diabetes, obesity & metabolism . 2018,第9期

机译：杜拉蛋白单疗法的疗效和安全性与多期，双盲，随机，平行，有效的比较器，III期试验中的2型糖尿病患者的肺血管肽相比
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. Efficacy of the Chinese herbal formula CUF2 in the treatment of childhood asthma: Animal experiment, in vitro study and randomized, double-blinded, placebo-controlled clinical trial. [D] . Wong, Yeuk Oi. 2006

机译：中药配方CUF2在治疗儿童哮喘中的功效：动物实验，体外研究以及随机，双盲，安慰剂对照的临床试验。
6. A phase III randomized multicentre double blind active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial [O] . Heinz Gisslinger, Veronika Buxhofer‐Ausch, Juri Hodisch, -1

机译：TEAM‐ET 2·0试验进行了一项III期随机多中心双盲主动对照试验以比较两种不同的阿那格雷内酯制剂在原发性血小板增多症患者中的疗效和安全性
7. SAT0139 A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS [O] . Xiaofeng Zeng, Yongfu Wang, Zhenyu Jiang, 2019

机译：SAT0139多期，随机，双盲，并行主动控制的临床试验比较HLX01和欧洲 - 食宿的药代动力学，药效学，安全性和探索性疗效，作为中华色血肿性关节炎的中学患者的新迹象

A phaseIIIrandomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – theTEAM‐ET2·0 trial

著录项

引文网络

相似文献

相关主题

期刊订阅